Stocks · News reference
Immutep Limited announced the receipt of a €1.36 million (approximately A$2.16 million) cash payment from the French Government under the Crédit d'Impôt Recherche (CIR) program for 2025 R&D activities.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Immutep Limited reported health-related quality of life (HRQoL) data from its investigator-initiated EFTISARC-NEO Phase II trial, which is being presented at the ESMO Congress 2026.
• Late-breaking poster will present data from the first-in-human Phase I study of IMP761, a first-in-class LAG-3 agonist antibody, in healthy volunteers
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is pleased to announce